At Bayer we’re visionaries, driven to solve the world’s toughest challenges and striving for a world where 'Health for all Hunger for none’ is no longer a dream, but a real possibility. We’re doing it with energy, curiosity and sheer dedication, always learning from unique perspectives of those around us, expanding our thinking, growing our capabilities and redefining ‘impossible’. There are so many reasons to join us. If you’re hungry to build a varied and meaningful career in a community of brilliant and diverse minds to make a real difference, there’s only one choice.

Associate Principal Scientist - Spatial multi-omics 

At Bayer Pharmaceuticals, we are dedicated to realizing our vision of treating the untreatable, curing diseases, and offering hope. If you’re looking to build a meaningful career within a community of creative and diverse individuals committed to making a difference, you’ve come to the right place. Bring your ideas, questions, passions, and unique perspectives, and join us today. We believe that your career journey should be defined by your unique skills and aspirations, not just a job title. Our team is made up of real people with energy, initiative, curiosity, and dedication who are eager to drive positive change.

YOUR TASKS AND RESPONSBILITIES

The primary responsibilities of the Associate Principal Scientist – Spatial multi-omics are to:

• Independently design, optimize, and perform high-sensitivity and high-spatial resolution LC-MS experiments for proteomics, metabolomics, and lipidomics (multi-omics);
• Prepare and process complex biological samples, e.g., biofluids for bulk and tissue sections, with laser microdissection for spatial multi-omics LC-MS analysis;
• Work closely with biologists and other scientists to integrate LC-MS multi-omics data with other omics and clinical data sets for understanding of biological systems;
• Collaborate with data science experts to develop and implement data post-processing pipelines;
• Translate complex data into meaningful biological insights, contributing to drug target discovery, biomarker translation, disease understanding, and elucidation of drug modes of action;
• Work with internal and external partners to generate high-quality metabolomics, lipidomics, and proteomics datasets that will enable translation from pre-clinical experiments to clinical applications;
• Summarize and present results to project team members and collaborators.

 WHO YOU ARE

Bayer seeks an incumbent who possesses the following:

Required qualifications:

• PhD in relevant fields such as chemistry, biochemistry, or biology; 
• Proven experience in completing complex scientific projects, and conducting work independently as well as within a team, collaboratively in a multidisciplinary environment;
• Advanced skills and deep, hands-on experience in high-resolution LC-MS and MS analysis covering metabolomics, lipidomics, and proteomics, with expertise in sample preparation for complex matrices including spatial analysis;
• You are driven by curiosity, advanced science, and innovation, deploying a strong analytical, investigative, and solution-oriented mindset while being capable of completing detailed documentation of experiments and results to enable data-driven decisions.

Preferred qualifications:

• PhD in relevant fields such as chemistry, biochemistry, or biology, with 3+ years of post-graduate experience in multi-omics data generation and processing, with a track record of publications and presentations at scientific meetings, enabled by excellent written and oral communication skills.

Employees can expect to be paid a salary between $124,960.00 - $187,440.00. Additional compensation may include a bonus or commission (if relevant). Additional benefits include healthcare, vision, dental, retirement, PTO, sick leave, etc.

This salary range is merely an estimate and may vary based on an applicant’s location, market data/ranges, skills, prior relevant experience, certain degrees and certifications, and other relevant factors.

This posting will be available for application until at least 03/12/2026